Intravitreal Quantum Dots (QD) for Advanced Retinitis Pigmentosa (RP) (QUANTUM)

Retinitis Pigmentosa Clinical Trial

Official title:

Intravitreal Quantum Dots (QD) for Advanced Retinitis Pigmentosa (QUANTUM): a Pilot, Randomized, Double-masked, Sham-controlled, Clinical Device Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05841862
• Other study ID #: 2C Tech-002
• Status: Not yet recruiting
• Phase: N/A
• Start date: March 2024
• Est. completion date: March 2025

Study information

• Verified date: April 2023
• Source: 2C Tech Corp
• Contact: Astrid Berthe
• Phone: (949) 461-1080
• Email: aberthe[@]2ctechcorp.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Pilot, randomized, observer and participant masked, sham and fellow eye controlled, interventional clinical device trail to evaluate the safety and effectiveness of the 2C-QD device to improve visual function in adults with advanced Retinitis Pigmentosa (RP).

Description:

Subjects will be informed about the study and potential risks and benefits, and then will provide written informed consent prior to study procedures being performed. Subjects will be screened for eligibility against criteria set forth within the clinical protocol. If subjects are eligible, they will be randomized to receive an intravitreal injection of the 2C-QD device in one eye, and the fellow eye will receive a sham injection and serve as the control. Subjects will then be following for 180 days, through 9 visits.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 20
• Est. completion date: March 2025
• Est. primary completion date: March 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or female adults, aged 18 years or older on the day of screening

2. Clinical diagnosis of bilateral RP, based on two or more of the following: clinical features, visual field testing, retinal imaging, electrophysiological measures, or genetic testing

3. BCVA of 6/60 (logMAR 1.0) or worse in both eyes, with loss of vision due to RP in the opinion of the Investigator.

4. Central visual field of less than 20 degrees in both eyes

5. Be able to follow instructions and ambulate

6. Be able to complete at least one mobility course at highest luminance level using each eye separately

7. Be able and willing to provide written informed consent, attend all scheduled visits and comply with all study procedures

8. For females capable of becoming pregnant, agree to have urine pregnancy testing (must be negative) and must not be lactating; and must agree to use a medically acceptable form of birth control throughout the study duration. Women considered capable of becoming pregnant include all females who have experienced menarche and have not experienced menopause (as defined by amenorrhea for greater than 12 consecutive months) or have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy). Acceptable forms of birth control are spermicide with barrier, oral contraceptive, injectable or implantable method of contraception, transdermal contraceptive, intrauterine device, or surgical sterilization of partner. For non-sexually active females, abstinence will be considered an acceptable form of birth control.

Exclusion Criteria:

1. Presence of severe systemic disease resulting in a life expectancy shorter than 1 year

2. Presence of retinal or optic nerve disease other than RP in either eye including cystoid macular oedema (CMO), glaucoma or ocular hypertension (IOP= 25mmHg), diabetic retinopathy, retinal vein occlusion, and age-related macular degeneration.

3. Be currently using any topical therapy for CMO (e.g., carbonic anhydrase inhibitors, corticosteroids, NSAIDs) in either eye.

4. Have the presence of an ocular media opacity in either eye, which in the opinion of the Investigator, will preclude an accurate evaluation at any time during the study

5. Have the presence of active ocular or systemic infection or inflammation, or any history of intraocular inflammation in either eye

6. Have had a prior vitrectomy in either eye

7. Have a history of amblyopia in either eye

8. Have current or former high myopia (>6 dioptres) in either eye

9. Have undergone ocular surgery within 6 months of the screening visit in either eye or have planned ocular surgery in either eye

10. Have one eye that is ineligible, or have asymmetrical ocular disease defined as a greater than 15 letter difference between the eyes based on BCVA results.

11. Have participated in any study involving an investigational drug or device within the past 30 days or have ongoing participation in a study with an investigational drug or device or have participated in a clinical trial of gene or cell therapy at any time

12. Have any clinical evidence that the Investigator feels would place the subject at increased risk with the investigational product

Related Conditions & MeSH terms

• Retinitis
• Retinitis Pigmentosa

Intervention

Device:
• 2C-QD
Quantum Dot
• Sham 2C-QD
Sham Intravitreal Injection

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
2C Tech Corp	ORA, Inc.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Monocular navigation performance	measured based on the ability to navigate the course under different light levels (defined as luminance) using the mobility course.	baseline to week 2
Secondary	Monocular navigation performance	measured using luminance level to complete the mobility course	baseline to week 4, 12, 24, 52
Secondary	binocular navigation performance	measured using luminance level to complete the mobility course	baseline to week 2, 4, 12, 24, 52
Secondary	monocular retinal sensitivity	measured using Octopus full-field static perimetry	baseline to week 2, 4, 12, 24, 52
Secondary	monocular best-corrected visual acuity (BCVA)	change in BCVA	baseline to week 2, 4, 12, 24, 52
Secondary	ellipsoid zone area	measured using spectral domain (SD) optical coherence tomography (OCT)	baseline to week 2, 4, 12, 24, 52